CN117338691A - 控油组合物及其制备方法 - Google Patents
控油组合物及其制备方法 Download PDFInfo
- Publication number
- CN117338691A CN117338691A CN202311576942.XA CN202311576942A CN117338691A CN 117338691 A CN117338691 A CN 117338691A CN 202311576942 A CN202311576942 A CN 202311576942A CN 117338691 A CN117338691 A CN 117338691A
- Authority
- CN
- China
- Prior art keywords
- extract
- component
- oil control
- control composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 115
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 25
- 230000035876 healing Effects 0.000 claims abstract description 24
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 17
- 230000002087 whitening effect Effects 0.000 claims abstract description 14
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 10
- 230000000149 penetrating effect Effects 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 21
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 19
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 19
- 241000207965 Acanthaceae Species 0.000 claims description 18
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 17
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 17
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 17
- 239000011425 bamboo Substances 0.000 claims description 17
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 claims description 17
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 244000308505 Filipendula ulmaria Species 0.000 claims description 7
- 235000016622 Filipendula ulmaria Nutrition 0.000 claims description 7
- 241001071795 Gentiana Species 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 241000207199 Citrus Species 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- 235000020971 citrus fruits Nutrition 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 claims description 5
- 235000008658 Artemisia capillaris Nutrition 0.000 claims description 4
- 241000092668 Artemisia capillaris Species 0.000 claims description 4
- 244000080208 Canella winterana Species 0.000 claims description 4
- 235000008499 Canella winterana Nutrition 0.000 claims description 4
- 241000208680 Hamamelis mollis Species 0.000 claims description 4
- 244000297179 Syringa vulgaris Species 0.000 claims description 4
- 235000004338 Syringa vulgaris Nutrition 0.000 claims description 4
- 240000001519 Verbena officinalis Species 0.000 claims description 4
- 229940017545 cinnamon bark Drugs 0.000 claims description 4
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims description 4
- 235000020725 licorice root extract Nutrition 0.000 claims description 4
- 229940051810 licorice root extract Drugs 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 4
- 229940118846 witch hazel Drugs 0.000 claims description 4
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims description 3
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 claims description 3
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 claims description 3
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 claims description 3
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 244000082204 Phyllostachys viridis Species 0.000 claims 1
- 240000004064 Poterium sanguisorba Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011148 porous material Substances 0.000 abstract description 16
- 230000028327 secretion Effects 0.000 abstract description 16
- 208000027418 Wounds and injury Diseases 0.000 abstract description 13
- 206010052428 Wound Diseases 0.000 abstract description 12
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 230000008021 deposition Effects 0.000 abstract description 3
- 239000000049 pigment Substances 0.000 abstract description 3
- 239000003921 oil Substances 0.000 description 61
- 210000003491 skin Anatomy 0.000 description 58
- 230000000694 effects Effects 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 18
- 241001330002 Bambuseae Species 0.000 description 16
- 230000001815 facial effect Effects 0.000 description 13
- 206010000496 acne Diseases 0.000 description 12
- 208000002874 Acne Vulgaris Diseases 0.000 description 11
- 206010039792 Seborrhoea Diseases 0.000 description 11
- 239000004519 grease Substances 0.000 description 11
- 230000037312 oily skin Effects 0.000 description 11
- 230000001186 cumulative effect Effects 0.000 description 10
- 208000020154 Acnes Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 244000173853 Sanguisorba officinalis Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000208681 Hamamelis virginiana Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 230000005808 skin problem Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 241001672694 Citrus reticulata Species 0.000 description 3
- 241000202662 Eleutherococcus trifoliatus Species 0.000 description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- YSXFFLGRZJWNFM-UHFFFAOYSA-N 5-hydroxy-2-(4-hydroxyphenyl)-3,6,7-trimethoxychromen-4-one Chemical compound COC=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C=C1 YSXFFLGRZJWNFM-UHFFFAOYSA-N 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000775848 Syringa oblata Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- CDPNZXRDLPGARW-UHFFFAOYSA-N Axillarin Natural products COC1=C(Oc2c(O)c(O)c(OC)cc2C1=O)c3ccc(O)c(O)c3 CDPNZXRDLPGARW-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 1
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241001135871 Gentiana scabra Species 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- XWIDINOKCRFVHQ-UHFFFAOYSA-N Spinacetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C(OC)=C(O)C=C3O2)O)=C1 XWIDINOKCRFVHQ-UHFFFAOYSA-N 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- HEYZWPRKKUGDCR-QBXMEVCASA-N Swertiamarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@]2(O)CCOC(=O)C2=CO1 HEYZWPRKKUGDCR-QBXMEVCASA-N 0.000 description 1
- HEYZWPRKKUGDCR-WRMJXEAJSA-N Swertiamarin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1 HEYZWPRKKUGDCR-WRMJXEAJSA-N 0.000 description 1
- 241001104043 Syringa Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- KIGVXRGRNLQNNI-UHFFFAOYSA-N axillarin Chemical compound COC=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 KIGVXRGRNLQNNI-UHFFFAOYSA-N 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000036211 hyaluronic acid binding proteins Human genes 0.000 description 1
- 108091010998 hyaluronic acid binding proteins Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- UWBHHFACDVJLQC-UHFFFAOYSA-N spinacetin Natural products COc1c(O)cc2OC(=C(O)C(=O)c2c1O)c3ccc(O)c(C)c3 UWBHHFACDVJLQC-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本申请具体公开了一种控油组合物及其制备方法,控油组合物包括保湿组分、抗菌消炎提取物组分、促愈提取物组分、美白提取物组分和渗透组分,控油组合物各个组分之间相互协调,能够有效消除受损肌肤表面的炎症,受损肌肤表面创口愈合后,毛孔收敛,皮肤恢复弹性,减少皮脂腺的油脂分泌,同时,配合调节肌肤表面的水油平衡,起到长效控油的作用;除此之外,受损肌肤在愈合过程中能够有效防止色素沉积,使得肌肤颜色均一。
Description
技术领域
本申请涉及化妆品的技术领域,更具体地说,它涉及一种控油组合物及其制备方法。
背景技术
油性肌肤是因人体皮脂腺分泌旺盛,导致人体面部油腻、毛孔粗大,大部分情况下还会伴随有面部痤疮、粉刺、痘痘等皮肤问题。随着人们作息不规律以及偏向于油腻辛辣食品的不良饮食习惯,导致油脂分泌过多,进一步加重了油性肌肤的困扰。
市面上存在较多的控油护肤产品,一般采用如下手段:第一,控油护肤品中添加收缩毛孔的功效性成分,例如,氧化锌、硫酸锌等无机颗粒,通过吸附堵塞出油毛孔的机理,以期望减少皮肤表面的油脂含量,改善油光满面的问题,但对于皮脂分泌过于旺盛的肤质,油脂无法及时排出,在毛孔内氧化,反而更容易引起毛孔堵塞,造成皮肤炎症、面部痤疮等皮肤问题加重。
第二,在控油护肤品中添加维生素,以维生素B6作为油脂调理的主要成分,但维生素B6难以对所有油性皮肤起到较好的控油效果,维生素B6仅能够针对伴随发炎现象的脂漏性油性肤质进行调理。
第三,由于油性皮肤往往是因为雄性激素分泌过剩,因此,行业内会在控油护肤品使用低剂量的雌性性激素作为控制剂,抑制皮脂分泌量,例如***、雌固酮等,但激素往往容易导致皮肤屏障受损,皮肤变得敏感脆弱,并且影响面部蛋白质的合成,皮肤细胞凋零,容易造成皮肤萎缩。
第四,控油护肤品中使用角质剥离溶解剂,例如水杨酸,通过水杨酸溶解毛孔中的角质栓塞,收敛毛孔,从而起到一定的控油作用。但水杨酸有一定的刺激性,且角质层变薄会导致皮肤表面失去保水能力,皮肤屏障层受损。
上述控油产品不仅难以对油性肤质进行有效地起到长效控油改善作用,还容易刺激本就受损的皮肤屏障层,尤其是皮肤带有创口,控油功效的组合物容易刺激创口,影响创口的愈合。
发明内容
为了解决传统控油产品难以长效控油且容易刺激皮肤上的创口导致创口难以愈合的问题,本申请提供一种控油组合物及其制备方法。
第一方面,本申请提供一种控油组合物,采用如下的技术方案:
一种控油组合物,包括保湿组分、抗菌消炎提取物组分、促愈提取物组分、美白提取物组分和渗透组分;
所述保湿组分按照重量份计算,包括1.5~4份多元醇保湿剂;
所述抗菌消炎提取物组分按照重量份计算,包括0.2~0.7份龙胆根提取物、2~5份柑橘果皮提取物、1~5份北美金缕梅提取物和3~5份榆绣线菊花提取物;
所述促愈提取物组分按照重量份计算,包括0.2~0.5份胀果甘草根提取物、1~4份姜根提取物和0.5~1份地榆根提取物;
所述美白提取物组分按照重量份计算,包括2~3份乳酸菌发酵提取物、0.1~0.2份酵母发酵产物、2~5份茵陈蒿提取物和1~5份马鞭草花水;
所述渗透组分按照重量份计算,包括0.5~1份欧丁香提取物、1~5份肉桂树皮提取物和0.5~1份聚甲基倍半硅氧烷。
进一步的,所述多元醇保湿剂包括丁二醇和1,2-己二醇,所述丁二醇和1,2-己二醇的重量比为(1~3):(0.5~1)。
进一步的,所述聚甲基倍半硅氧烷的粒径为2~5μm。
进一步的,所述组合物中还包括油脂吸附调节组分,所述油脂吸附调节组分包括印度簕竹茎粉,所述印度簕竹茎粉的重量份为2~4份。
进一步的,所述印度簕竹茎粉的粒径为1~10μm。
进一步的,所述油脂吸附调节组分还包括蒙脱土,所述蒙脱土的重量份为0.5~1份。
进一步的,所述蒙脱土的粒径为5~10μm。
进一步的,所述组合物中还包括对羟基苯乙酮,所述对羟基苯乙酮的重量份为0.1~0.5份。
第二方面,本申请提供一种控油组合物的制备方法,采用如下技术方案:
一种控油组合物的制备方法,包括如下步骤:
将多元醇保湿剂加热溶解,配制成溶剂;再向溶剂中加入渗透组分和油脂吸附调节组分搅拌混匀,得到混合液;向混合液中再加入抗菌消炎提取物组分、促愈提取物组分和美白提取物组分,搅拌混匀后陈化,得到控油组合物。
本申请的技术方案至少具备如下优势:
第一,本申请中通过采用保湿组分、抗菌消炎提取物组分、促愈提取物组分、美白提取物组分和渗透组分等多种组分的协同配合下,能够有效地起到长效控油的作用,尤其是针对带有创口的皮肤可进行促愈合,高效改善油性肤质。其具体机理如下:
抗菌消炎提取物组分包括了龙胆(GENTIANA SCABRA)根提取物、柑橘(CITRUSRETICULATA)果皮提取物、北美金缕梅(HAMAMELIS VIRGINIANA)提取物、榆绣线菊(SPIRAEAULMARIA)花提取物;
龙胆根提取物中富含环烯醚萜类活性化合物,例如马钱子苷酸、獐牙菜苦苷、龙胆苦苷和三花龙胆苷,环烯醚萜类活性化合物能够有效地抑制脂多糖(LPS)引发NO释放,从而降低皮肤炎症反应出现的可能性,起到抗炎作用;由于革兰氏阴性菌外膜主要成分为LPS,龙胆根提取物可以抑制革兰氏阴性菌引起的皮肤化脓等问题;同时,龙胆根提取物对荧光素酶的有很好的活化效果,对特异性皮炎和过敏有作用,可抑制刺激。
柑橘果皮提取物中柑橘多酚类物质还能通过阻碍致炎细胞因子的表达途径来实现其抗炎作用富含有强烈广谱的抗菌性,对致痤疮菌也有很好的抑制效果。
北美金缕梅提取物中富含没食子酸以及单宁等活性抗炎化合物,能够针对痤疮,湿疹或牛皮癣等类型的皮肤问题起到有效治疗;同时,北美金缕梅提取物所具有的天然收敛性质可以帮助收缩毛孔,清除面部痤疮、细菌和面部油脂。
榆绣线菊花提取物含有调理人体皮脂腺的多酚成分,能有效调节皮脂腺的异常分泌,抑制炎症的产生,从根本上调理肌肤应激反应;龙胆根提取物、柑橘果皮提取物以及北美金缕梅提取物分别针对不同类型炎症进行治疗,配合北美金缕梅提取物以及榆绣线菊花提取物的皮脂腺收缩、调理作用,从根源上调理油性肌肤状态。
促愈提取物组分包括胀果甘草(GLYCYRRHIZA INFLATA)根提取物、姜(ZINGIBEROFFICINALE)根提取物、地榆(SANGUISORBA OFFICINALIS)根提取物;
胀果甘草根提取物中富含甘草酸二钾,甘草酸二钾主要是通过减少粒细胞的数量来减轻创面炎症反应、促进肉芽组织形成、成纤维细胞的快速增殖、使上皮爬行速度增快、新生的毛细血管增多,从而加速组织创面愈合的过程。
姜根提取物中含有姜辣素,可以增强皮肤活性,活化肌肤,从而刺激纤维细胞的快速增殖;但姜辣素容易刺激肌肤,使得面部毛细血管扩张,因此,搭配甘草酸二钾,通过抑制透明质酸酶的活性、抑制组胺的释放,起到肌肤镇静作用,有效化解姜根提取物的刺激性。
地榆根提取物含有鞣质、皂苷和黄酮等活性成分,通过改善人面部皮肤弹性,发挥抗透明质酸结合蛋白参与透明质酸解聚介导的透明质酸降解活性和抗皱活性,起到较好的抗皱作用;同时,还能显著降低内皮素转化酶活性,抑制角质形成层细胞分泌内皮素-1,显著减轻由紫外线B照射引起的色素沉着。
促愈提取物组分能够刺激肌肤真皮层的胶原蛋白以及弹性纤维再生,还能够促进肉芽组织形成,使得伤口在愈合过程中维持受损前的弹性,从而能够辅助抗菌消炎提取物组分缩小油性肌肤表面的毛孔,降低皮肤表面油脂分泌。
美白提取物组分包括乳酸菌发酵提取物、酵母发酵产物提取物、茵陈蒿(ARTEMISIA CAPILLARIS)提取物、马鞭草(VERBENA OFFICINALIS)花水;
乳酸菌发酵提取物中含有乳酸和维生素系列群,乳酸就有增进上皮细胞新陈代谢的速度,促使肌肤更新,抑制黑色素酶的活性。
酵母发酵产物提取物酵母菌发酵产生的液体中的成分被认为能够刺激皮肤细胞的新陈代谢,促进细胞再生过程,从而改善肤色不均和细纹等问题。
茵陈蒿提取物中含有丰富的黄酮类物质,例如spinacetin、axillarin、5,4'-二羟基-3,6,7-三甲氧基黄酮喷杜素、茵陈黄酮,上述黄酮类物质抑制酪氨酸酶的活性,减少黑色素的产生,从而达到美白的功效。
马鞭草花水中含有齐墩果酸、熊果酸、黄酮类、马鞭草苷等成分,提取物可以刺激成纤维细胞增殖,清除自由基,消除水肿,抑制黑色素瘤细胞B16增殖,具有美白功效。
美白提取物组分能够有效弥补肌肤受损后黑色素增加导致的色素沉着问题,配合促愈提取物组分使用,能够使得肌肤在受损消炎愈合过程中恢复均一肤色,避免愈合部位出现色素沉积。
渗透组分包括欧丁香(SYRINGA VULGARIS)提取物、聚甲基倍半硅氧烷、肉桂(CINNAMOMUM CASSIA)树皮提取物;
欧丁香提取物中所含丁香油、丁香油酚、丁香醇等物质,肉桂树皮提取物中富含肉桂醛,上述有效成分的极性小,容易通过角质层,起到较好的渗透作用;
聚甲基倍半硅氧烷具有疏松多孔结构,能够充分吸附欧丁香提取物和肉桂树皮提取物等不溶于水的促渗透组分,有助于渗透组分更好地分散在控油组合物中,辅助欧丁香提取物以及肉桂醛组分进行有效渗透。
保湿组分包括丁二醇、1,6-己二醇等多元醇保湿剂,多元醇保湿剂能够锁住油性肌肤表面的水分,抑制皮脂腺过度分泌油脂,控制皮肤表面的水油平衡。辅助控油组合物起到高效控油的效果。
综上,本申请制得的控油组合物各个组分之间相互协调,能够有效消除受损肌肤表面的炎症,受损肌肤表面创口愈合后,毛孔收敛,皮肤恢复弹性,减少皮脂腺的油脂分泌,同时,配合调节肌肤表面的水油平衡,起到长效控油的作用;除此之外,受损肌肤在愈合过程中能够有效防止色素沉积,使得肌肤颜色均一。
第二,本申请中还加入了对羟基苯乙酮,对羟基苯乙酮具有天然抗氧活性,同时,对羟基苯乙酮与抗菌抗炎组分协同,作为防腐增效剂,通过抑制微生物细胞壁的形成或者影响细胞膜功能或者致使细菌、霉菌等物质的蛋白质改性等方式,降低控油组合物中水和酵母发酵产物提取物等营养组分导致有害菌滋生的可能性。
第三,本申请中还加入了油脂吸附调节组分,油脂吸附调节组分包括印度簕竹茎粉和蒙脱土;印度簕竹茎粉为天然硅质成分,内部含有多孔隙结构,可代替传统二氧化硅等矿物质粉末;蒙脱土的孔隙结构丰富,与印度簕竹茎粉配合能够充分吸附难溶于水的提取物组分,有助于后期将控油组合物配制成稳定均一的水溶液。同时,印度簕竹茎粉能够在皮肤表面形成吸附层,吸附皮肤表面产生的油脂,具备天然强效去油光,平衡水油,呵护皮脂膜的功效。
第四,本申请中调控聚甲基倍半硅氧烷、印度簕竹茎粉和蒙脱土的粒径大小,使得其既能够充分吸附抗菌消炎提取物组分等活性物质,有利于控油组合物在肌肤表面充分释放;同时,由于肌肤毛孔的
实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例对本申请的技术方案进行进一步说明。
若无特殊说明,龙胆根提取物、柑橘果皮提取物、北美金缕梅提取物榆绣线菊花提取物、胀果甘草根提取物、姜根提取物、地榆根提取物、乳酸菌发酵提取物、酵母发酵产物、茵陈蒿提取物、马鞭草花水、欧丁香提取物、肉桂树皮提取物、印度簕竹茎粉均为定制产品。
实施例
实施例1-8
一种控油组合物,其成分如下表1:
表1.控油组合物组成
注释:以上实施例中印度簕竹茎粉的粒径为1~10μm、聚甲基倍半硅氧烷的 粒径为2~5μm、蒙脱土的粒径为5~10μm;
“/”表示不添加。
实施例1-8按照如下步骤制备得到:
按照各原料的重量,分别称取备用;
在搅拌的条件下,将对羟基苯乙酮、丁二醇和1,2-己二醇加热80℃溶解至透明无颗粒后,倒入纯水中搅拌混合均匀,得到溶剂;
在搅拌的条件下,将聚甲基倍半硅氧烷、印度簕竹茎粉和蒙脱土混合搅拌混合均匀,得到混合料;
在搅拌的条件下,温度60℃,将溶剂缓慢加入混合料中,搅拌,降温至40℃,得到混合液;
在搅拌的条件下,控温40℃下,向混合液中依次加入龙胆根提取物、柑橘果皮提取物、茵陈蒿提取物、胀果甘草根提取物、乳酸菌发酵提取物、酵母发酵产物提取物、北美金镂梅树皮/叶提取物、马鞭草花水、榆绣线菊花提取物、肉桂树皮提取物、姜根提取物和地榆根提取物,继续搅拌15min,室温陈化,得到控油组合物。
实施例9-10
一种控油组合物,与实施例1的区别点在于印度簕竹茎粉、聚甲基倍半硅氧烷、蒙脱土的粒径不同,具体如下:
实施例9中印度簕竹茎粉的粒径为15~25μm、聚甲基倍半硅氧烷的 粒径为10~25μm、蒙脱土的粒径为10~25μm;
实施例10中印度簕竹茎粉的粒径为0.1~0.5μm、聚甲基倍半硅氧烷的 粒径为0.1~1μm、蒙脱土的粒径为0.1~1μm。
对比例
对比例1-5
一种控油组合物,其成分如下:
表2.控油组合物的成分
注释:以上实施例中印度簕竹茎粉的粒径为1~10μm、聚甲基倍半硅氧烷的 粒径为2~5μm、蒙脱土的粒径为5~10μm。
性能检测
1.体外透皮试验:以新鲜猪皮作为试验原料,新鲜猪皮来源于新鲜猪耳朵,要求猪耳朵光洁,对光观察无暗点,猪耳朵表面无任何伤痕。猪耳朵清洗除毛后,用手术刀将耳背剥离软骨,刮去脂肪组织,生理盐水洗净之后,切割成尺寸为2×2cm的样品,将样品浸泡在生理盐水中备用。
将样品放置在扩散池中,角质层向上,向接收池中加入生理盐水,置于37℃的恒温水浴中,转速为100r/min;平衡半小时后,取控油组合物0.1g均匀涂膜在样品的角质层面,分别于15min、30min、60min从接收池中抽取5mL溶液,并注入等量的新生理盐水,在297nm波长下,采用高效液相法进行含量测定,计算不同时间的累积渗透量,累积渗透量Q按照如下公式计算:;其中,K为接收池的容积,Cn为第n个取样点的浓度,Ci为第i个点的浓度。统计15min和60min两个时间节点的累积渗透量。
表3.实施例1-10以及对比例1-5的累积渗透量
结论:实施例1和对比例1-5形成单一对比例,其中,对比例5中由于缺少渗透组分,可以看出其与实施例1相比,在初始15min时累积渗透量较低,几乎接近于0,在后期涂抹60min后累积渗透量虽然增加,但其远低于实施例1在15min时的累积渗透量。对比例1-4中虽然含有渗透组分,但保湿组分、抗菌消炎提取物组分、促愈提取物组分以及美白提取物组分中含有的活性物质也对渗透性能起到辅助作用,对比例1-4的累积渗透量低于实施例1,表明了控油组合物中多个组分的有效配合能够在促进渗透方面起到协同增效的作用。
实施例1-3形成对比,成分虽然相同,但实施例1中的成分比例为较好的比例,累积渗透量在初始15min和60min均高于实施例2,表明能够被人体肌肤更好的吸收。但由于本申请中各个植物提取物的原料成本较高,虽然实施例3的累积渗透量优于实施例1,但考虑到成本问题,实施例1为较好的组合物配比。
实施例1、9-10形成对比,区别点仅在于印度簕竹茎粉、聚甲基倍半硅氧烷、蒙脱土的粒径不同。但对累积渗透量起到较为重要的影响,其原因在于:当印度簕竹茎粉、聚甲基倍半硅氧烷、蒙脱土的粒径越大时,短时间内活性物质被吸附在上述物质的孔隙结构中,难以高效释放,导致15min累积渗透量偏低;当印度簕竹茎粉、聚甲基倍半硅氧烷、蒙脱土的粒径过小时,上述物质容易出现团聚问题,从而导致了对各个活性组分的吸附效果差,15min累积渗透量较低,30min累积渗透量也偏低。
2.人体透皮试验:测验人员的年龄标准为18-40岁,油性肌肤,面部具有较为明显的粉刺和痘痘,面部存在痤疮等皮脂溢出性皮肤病,面部存在皮损;
测验人员无过敏体质者;无严重心、肝、肾功能损害及严重免疫功能低下者;无精神疾病及严重内分泌疾病者或妊娠以及口服避孕药者;无30天内参加药物临床试验者或其它试验者或有口服对试验结果有影响的药物者。
测验人员共150人,随机选择10人为一组,每一个实施例和对比例的实验样本数量为10,测试期间测验人员每日2次,早晚各一次;取本品适量涂于患处,共使用4周,全程不用其他药物作为辅助治疗。测验人员在纳入试验时(第0天)、试验开始后第1周、2周和第4周进行随访和临床评估。
检测项目包括:面部皮肤炎症程度、粉刺数目、肤色均匀改善程度、面部破损愈合程度以及皮肤油脂降低含量;
其中,面部皮肤炎症的程度采用皮肤红斑指数进行表征,使用VISIA-CR皮肤检测***,选定面部被测区域,主要测定各区域红斑指数EI值;
粉刺数目采用VISIA-CR皮肤检测***,选定面部被测区域,主要测定各区域粉刺数目;
肤色均匀程度采用如下方式进行检测:在测验人员面颊的皮损处和随机取检测点,检测点以表观亮度进行衡量,测定表观亮度的差值平均值;
面部破损愈合程度采用愈合面积占皮损面积的比例进行衡量,愈合的指标为皮损处无明显红肿,皮肤受损毛孔恢复至0.02~0.05mm2;
采用皮肤油脂测试仪对测验人员面部油脂含量的进行统计;
表4.面部皮肤炎症程度的跟踪变化
注释:均值的计算方式为取掉一个最大值和最小值,其余数值的平均数;
p<0.05表示具有显著差异性,p>0.05表示不具有显著差异性;
根据表4的检测结果可知,实施例1治疗1周后,其疗效显著,EI值的平均值降低至333.7,与治疗前,疗效具有显著差异性,测试人员面部的皮肤炎症减轻,治疗4周后,EI值降低至267.8,降幅明显,能够持续性的有效改善皮肤炎症。
而对比例2中由于缺少抗炎组分,其抗炎效果极差,治疗4周后几乎无疗效;对比例5中由于缺少渗透组分,其抗炎效果也较差,治疗4周后几乎无疗效;其原因在于渗透组分的缺失导致抗菌消炎提取物难以有效地穿过皮肤角质层,进行高效抗炎作用。
表5.粉刺数目的跟踪变化
根据表5的检测结果可知,实施例1治疗1周后,其疗效显著,粉刺数目的平均值降低至149,与治疗前,疗效具有显著差异性,测试人员面部的皮肤平整,粉刺数目降低,治疗4周后,粉刺数目降幅明显,能够持续性的有效改善皮肤问题。实施例5-7中,由于油脂平衡调节组分的改变,影响了粉刺数目的改善,从而导致粉刺数目偏高。
而对比例2中由于缺少抗炎组分,粉刺数目仍然较高,治疗4周后几乎无疗效;对比例5中由于缺少渗透组分,其粉刺数目也较高,治疗4周后几乎无疗效。
表7.肤色均匀程度的跟踪变化
根据表6的检测结果可知,对比例4中缺少美白提取物组分,面部色差在治疗4周后不降反升,表明随着治疗的进行,面部皮损处虽然愈合,但愈合过程中色素沉着,导致了L值增加。
表7.面部愈合程度的跟踪变化
根据表7的检测结果可知,对比例1中缺少保湿组分,影响了皮肤表面的水油平衡,导致了皮脂腺分泌仍然存在异常,皮损处难以愈合;对比例2中缺少抗菌消炎提取物组分,皮肤表面仍然存在炎症,也影响了皮损处难以愈合;对比例3中缺少促愈提取物组分,皮肤愈合的程度减慢。
表8.面部油脂含量的跟踪变化
根据表8的检测结果可知,缺乏保湿组分、抗菌消炎提取物组分、促愈提取物组分以及渗透组分均会影响到皮肤皮脂腺的分泌状况,难以调节皮肤表面的水油平衡,同时,虽然对比例5中设置有油脂吸附调节组分,但其仅仅是针对油脂进行吸附,难以根治油脂的分泌,反而容易加重油性皮肤的油脂分泌问题。
实施例1-10均进行了人体安全贴片检测,检测过程中无阳性和刺激性情况出现,表明此组合物能够使用于皮肤皮损处。并且根据表3-8的检测结果可知:控油组合物各个组分之间相互协调,能够有效消除受损肌肤表面的炎症,受损肌肤表面创口愈合后,毛孔收敛,皮肤恢复弹性,减少皮脂腺的油脂分泌,同时,配合调节肌肤表面的水油平衡,起到长效控油的作用;除此之外,受损肌肤在愈合过程中能够有效防止色素沉积,使得肌肤颜色均一。
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
且,以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (9)
1.一种控油组合物,其特征在于,包括保湿组分、抗菌消炎提取物组分、促愈提取物组分、美白提取物组分和渗透组分;
所述保湿组分按照重量份计算,包括1.5~4份多元醇保湿剂;
所述抗菌消炎提取物组分按照重量份计算,包括0.2~0.7份龙胆根提取物、2~5份柑橘果皮提取物、1~5份北美金缕梅提取物和3~5份榆绣线菊花提取物;
所述促愈提取物组分按照重量份计算,包括0.2~0.5份胀果甘草根提取物、1~4份姜根提取物和0.5~1份地榆根提取物;
所述美白提取物组分按照重量份计算,包括2~3份乳酸菌发酵提取物、0.1~0.2份酵母发酵产物、2~5份茵陈蒿提取物和1~5份马鞭草花水;
所述渗透组分按照重量份计算,包括0.5~1份欧丁香提取物、1~5份肉桂树皮提取物和0.5~1份聚甲基倍半硅氧烷。
2.如权利要求1所述的控油组合物,其特征在于:所述多元醇保湿剂包括丁二醇和1,2-己二醇,所述丁二醇和1,2-己二醇的重量比为(1~3):(0.5~1)。
3.如权利要求1所述的控油组合物,其特征在于:所述聚甲基倍半硅氧烷的粒径为2~5μm。
4.如权利要求1所述的控油组合物,其特征在于:所述组合物中还包括油脂吸附调节组分,所述油脂吸附调节组分包括印度簕竹茎粉,所述印度簕竹茎粉的重量份为2~4份。
5.如权利要求4所述的控油组合物,其特征在于:所述印度簕竹茎粉的粒径为1~10μm。
6.如权利要求4所述的控油组合物,其特征在于:所述油脂吸附调节组分还包括蒙脱土,所述蒙脱土的重量份为0.5~1份。
7.如权利要求6所述的控油组合物,其特征在于:所述蒙脱土的粒径为5~10μm。
8.如权利要求1所述的控油组合物,其特征在于:所述组合物中还包括对羟基苯乙酮,所述对羟基苯乙酮的重量份为0.1~0.5份。
9.权利要求4-8中任意一项所述的控油组合物的制备方法,其特征在于:将多元醇保湿剂加热溶解,配制成溶剂;再向溶剂中加入渗透组分和油脂吸附调节组分搅拌混匀,得到混合液;向混合液中再加入抗菌消炎提取物组分、促愈提取物组分和美白提取物组分,搅拌混匀后陈化,得到控油组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311576942.XA CN117338691A (zh) | 2023-11-24 | 2023-11-24 | 控油组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311576942.XA CN117338691A (zh) | 2023-11-24 | 2023-11-24 | 控油组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117338691A true CN117338691A (zh) | 2024-01-05 |
Family
ID=89365172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311576942.XA Pending CN117338691A (zh) | 2023-11-24 | 2023-11-24 | 控油组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117338691A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726067A (zh) * | 2023-07-24 | 2023-09-12 | 中国人民解放军空军特色医学中心 | 一种自组装微沉淀组合物及其皮肤用凝胶、制备方法和应用 |
-
2023
- 2023-11-24 CN CN202311576942.XA patent/CN117338691A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726067A (zh) * | 2023-07-24 | 2023-09-12 | 中国人民解放军空军特色医学中心 | 一种自组装微沉淀组合物及其皮肤用凝胶、制备方法和应用 |
CN116726067B (zh) * | 2023-07-24 | 2024-04-16 | 中国人民解放军空军特色医学中心 | 一种自组装微沉淀组合物及其皮肤用凝胶、制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davis et al. | Wound healing. Oral and topical activity of Aloe vera | |
EA032439B1 (ru) | Композиции и способы для лечения поверхностных ран | |
CN108938513B (zh) | 一种清肤祛痘美颜霜及其制备方法 | |
CN106074206B (zh) | 一种护肤主剂、制备方法及其应用 | |
CN109276523A (zh) | 一种薄荷面膜液及其制备方法 | |
US20100062085A1 (en) | Treatment of damaged skin | |
US8557795B2 (en) | Composition containing Chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
CN115025024B (zh) | 一种祛痘消印组合物及其应用 | |
CN117338691A (zh) | 控油组合物及其制备方法 | |
CN111743830A (zh) | 一种祛痘组合物及其应用 | |
CN111588815B (zh) | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 | |
CN111228207B (zh) | 祛湿疹护臀霜及其制备方法 | |
CN111529470B (zh) | 一种复方祛痘舒敏凝胶剂及其制备方法 | |
CN112426390A (zh) | 一种天然中药祛痘组合物及其制备方法 | |
CN112426398A (zh) | 一种具有淡化痘印作用的祛痘组合物及其制备方法 | |
CN111281966B (zh) | 含地龙蛋白的组合物及其制备方法和应用 | |
CN113679765A (zh) | 白鲜皮提取物及其应用 | |
KR20100079586A (ko) | 엉겅퀴 추출물을 함유하는 항아토피 피부염 조성물 | |
Muhammed et al. | Effect of application of Fenugreek (Trigonella foenum-graecum) on skin wound healing in rabbits | |
CN108815111A (zh) | 一种中药祛斑美白修复组合物及其制备方法 | |
CN108938511B (zh) | 天然植物提取物的组合物及在皮肤保湿祛痘产品中的应用 | |
CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
KR102272771B1 (ko) | 홍화자 추출물 또는, 홍화자 및 빈랑자 혼합추출물을 유효성분으로 함유하는 스트레스 자극에 의한 피지분비완화 또는 개선용 화장료 조성물 | |
WO2015010372A1 (zh) | 一种用于治疗青春痘色素沉斑和美白的膏霜 | |
CN108938514B (zh) | 一种清肤祛痘液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |